Shasun Pharmaceuticals has signed the Joint Venture (JV) pact with SeQuent. The JV Company has been formed to develop, manufacture and sell veterinary products including both API (Active Pharmaceutical Ingredients) and formulations to cater to the global market.

In line with the JV pact, the company has also executed on March 07, 2014 a Slump Sale agreement transferring its Vizag facility to JV Company. SeQuent and Shasun will hold 73% and 27% respectively in the JV Company.

JV Company is expected to be operational in the first quarter of 2014-15, subject to the customary closing conditions.

Shasun Pharmaceuticals manufactures active pharmaceutical ingredients (APIs), their intermediates and enteric coating excipients with a significant presence in some key generics. Shasun has created a strong product portfolio, building on its R&D Expertise, regulatory capabilities and multi scale production capacities. It is one of the largest producers of Ibuprofen worldwide.

Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×